Literature DB >> 27063952

Shift of microRNA profile upon orthotopic xenografting of glioblastoma spheroid cultures.

Bo Halle1,2,3, Mads Thomassen4,5, Ranga Venkatesan6, Vivek Kaimal6, Eric G Marcusson6, Sune Munthe7,8,4, Mia D Sørensen7,4, Charlotte Aaberg-Jessen9, Stine S Jensen7,4, Morten Meyer10, Torben A Kruse4,5, Helle Christiansen11, Steffen Schmidt11, Jan Mollenhauer11, Mette K Schulz8,4, Claus Andersen8,4, Bjarne W Kristensen7,4.   

Abstract

Glioblastomas always recur despite surgery, radiotherapy and chemotherapy. A key player in the therapeutic resistance may be immature tumor cells with stem-like properties (TSCs) escaping conventional treatment. A group of promising molecular targets are microRNAs (miRs). miRs are small non-coding RNAs exerting post-transcriptional regulation of gene expression. In this study we aimed to identify over-expressed TSC-related miRs potentially amenable for therapeutic targeting. We used non-differentiated glioblastoma spheroid cultures (GSCs) containing TSCs and compared these to xenografts using a NanoString nCounter platform. This revealed 19 over-expressed miRs in the non-differentiated GSCs. Additionally, non-differentiated GSCs were compared to neural stem cells (NSCs) using a microarray platform. This revealed four significantly over-expressed miRs in the non-differentiated GSCs in comparison to the NSCs. The three most over-expressed miRs in the non-differentiated GSCs compared to xenografts were miR-126, -137 and -128. KEGG pathway analysis suggested the main biological function of these over-expressed miRs to be cell-cycle arrest and diminished proliferation. To functionally validate the profiling results suggesting association of these miRs with stem-like properties, experimental over-expression of miR-128 was performed. A consecutive limiting dilution assay confirmed a significantly elevated spheroid formation in the miR-128 over-expressing cells. This may provide potential therapeutic targets for anti-miRs to identify novel treatment options for GBM patients.

Entities:  

Keywords:  Cancer stem cell; Glioblastoma; MicroRNA; Tumor stem cell

Mesh:

Substances:

Year:  2016        PMID: 27063952     DOI: 10.1007/s11060-016-2125-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  47 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

2.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

3.  Direct multiplexed measurement of gene expression with color-coded probe pairs.

Authors:  Gary K Geiss; Roger E Bumgarner; Brian Birditt; Timothy Dahl; Naeem Dowidar; Dwayne L Dunaway; H Perry Fell; Sean Ferree; Renee D George; Tammy Grogan; Jeffrey J James; Malini Maysuria; Jeffrey D Mitton; Paola Oliveri; Jennifer L Osborn; Tao Peng; Amber L Ratcliffe; Philippa J Webster; Eric H Davidson; Leroy Hood; Krassen Dimitrov
Journal:  Nat Biotechnol       Date:  2008-02-17       Impact factor: 54.908

4.  Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status.

Authors:  Xuan Zhou; Yu Ren; Lynette Moore; Mei Mei; Yongping You; Peng Xu; Baoli Wang; Guangxiu Wang; Zhifan Jia; Peiyu Pu; Wei Zhang; Chunsheng Kang
Journal:  Lab Invest       Date:  2010-01-04       Impact factor: 5.662

5.  Convection-enhanced delivery of an anti-miR is well-tolerated, preserves anti-miR stability and causes efficient target de-repression: a proof of concept.

Authors:  Bo Halle; Eric G Marcusson; Charlotte Aaberg-Jessen; Stine S Jensen; Morten Meyer; Mette K Schulz; Claus Andersen; Bjarne W Kristensen
Journal:  J Neurooncol       Date:  2015-10-01       Impact factor: 4.130

6.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.

Authors:  Jian Wang; Per Ø Sakariassen; Oleg Tsinkalovsky; Heike Immervoll; Stig Ove Bøe; Agnete Svendsen; Lars Prestegarden; Gro Røsland; Frits Thorsen; Linda Stuhr; Anders Molven; Rolf Bjerkvig; Per Ø Enger
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

7.  Mammalian microRNAs predominantly act to decrease target mRNA levels.

Authors:  Huili Guo; Nicholas T Ingolia; Jonathan S Weissman; David P Bartel
Journal:  Nature       Date:  2010-08-12       Impact factor: 49.962

8.  Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal.

Authors:  Jakub Godlewski; Michal O Nowicki; Agnieszka Bronisz; Shanté Williams; Akihiro Otsuki; Gerard Nuovo; Abhik Raychaudhury; Herbert B Newton; E Antonio Chiocca; Sean Lawler
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

9.  Differential development of neuronal physiological responsiveness in two human neural stem cell lines.

Authors:  Roberta Donato; Erik A Miljan; Susan J Hines; Sihem Aouabdi; Kenneth Pollock; Sara Patel; Frances A Edwards; John D Sinden
Journal:  BMC Neurosci       Date:  2007-05-25       Impact factor: 3.288

10.  MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1.

Authors:  Ariel Bier; Nis Giladi; Noan Kronfeld; Hae Kyung Lee; Simona Cazacu; Susan Finniss; Cunli Xiang; Laila Poisson; Ana C deCarvalho; Shimon Slavin; Elad Jacoby; Michal Yalon; Amos Toren; Tom Mikkelsen; Chaya Brodie
Journal:  Oncotarget       Date:  2013-05
View more
  2 in total

1.  Heterogenic expression of stem cell markers in patient-derived glioblastoma spheroid cultures exposed to long-term hypoxia.

Authors:  Tine Rosenberg; Charlotte Aaberg-Jessen; Stine Asferg Petterson; Bjarne Winther Kristensen
Journal:  CNS Oncol       Date:  2018-04-30

Review 2.  MicroRNAs at the Crossroad of the Dichotomic Pathway Cell Death vs. Stemness in Neural Somatic and Cancer Stem Cells: Implications and Therapeutic Strategies.

Authors:  Andrea Diana; Giuseppe Gaido; Cristina Maxia; Daniela Murtas
Journal:  Int J Mol Sci       Date:  2020-12-17       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.